Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: J Viral Hepat. 2014 Nov 24;22(8):675–681. doi: 10.1111/jvh.12368

Figure 2.

Figure 2

Kaplan Meier analysis of complete viral suppression (CVS) rates comparing tenofovir (TDF) monotherapy and entecavir (ETV) + TDF combination therapy as alternate therapies in patients with a partial virological response to ETV and HBV DNA levels >1,000 IU/mL at the time of switch